Covid-19 roundup: Abivax pulls the plug on its anti-inflammatory treatment; J&J says it could fall short on Q2 vaccine supply for EU — report
Another Covid-19 treatment is biting the dust after an independent Data Safety and Monitoring Board flagged it for lack of efficacy.
Paris-based Abivax shared last week that it’s slamming the brakes on its Phase IIb/III clinical trial for ABX464 in high-risk Covid patients. The study, dubbed miR-AGE, had already recruited 500 patients of the planned 1,034.
Researchers were testing the anti-inflammatory to see if it could prevent severe disease. But a planned interim analysis of data from 306 patients showed no difference between the drug and a placebo. ABX464 was well-tolerated and safe, Abivax noted.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
